The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors.

ABSTRACT:

Introduction

The prognostic factors associated with recurrent platinum-resistant ovarian cancer treated with immune checkpoint inhibitor (ICI) therapy need to be identified.

Methods

We retrospectively analyzed the efficacy of ICI therapy in patients with recurrent platinum-resistant ovarian cancer at our center. The number of CD8 + T cells and the expression of PD-L1 were assessed using immunohistochemical assays. A multi-analyte flow assay was used to detect the concentrations of 13 inflammatory cytokines. Both univariate and multivariate models were constructed using pretreatment clinical variables and cytokines.

Results

We included 71 patients with recurrent platinum-resistant ovarian cancer treated with at least two cycles of anti-programmed cell death 1 (PD-1); t

SUBMITTER: Pan B 

PROVIDER: S-EPMC12329967 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature